Home/Filings/4/A/0001209191-20-020744
4/A//SEC Filing

Levine James E. 4/A

Accession 0001209191-20-020744

CIK 0001610618other

Filed

Mar 22, 8:00 PM ET

Accepted

Mar 23, 7:12 PM ET

Size

5.6 KB

Accession

0001209191-20-020744

Insider Transaction Report

Form 4/AAmended
Period: 2019-09-24
Levine James E.
Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    2019-09-24$1.91/sh+30,000$57,24030,000 total
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  • [F2]On September 26, 2019, the reporting person filed a Form 4 which inadvertently reported that, following his open market purchase, he held 205,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person directly owned 30,000 shares of common stock.

Issuer

Cidara Therapeutics, Inc.

CIK 0001610618

Entity typeother

Related Parties

1
  • filerCIK 0001463151

Filing Metadata

Form type
4/A
Filed
Mar 22, 8:00 PM ET
Accepted
Mar 23, 7:12 PM ET
Size
5.6 KB